IGF2 and adrenal cortex carcinoma: Previous studies have clearly shown over-expression of IGF2 (Gicquel et al. 2001, Giordano et al. 2009, Laurell et al. 2009) or decreased expression of H19 (Gao et al. 2002, Giordano et al. 2009) in ACCs and demonstrated the potential of IGF2 as a biomarker for ACC diagnosis (Gicquel et al. 2001).